Your session is about to expire
← Back to Search
Amino Acid Formulation
Neuron012703 for Diabetic Neuropathy (Neuron012703 Trial)
Phase 2
Waitlist Available
Led By Gabriel Halperin, DPM
Research Sponsored by Targeted Medical Pharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 days
Awards & highlights
Summary
A clinical outcomes study measuring reduction in pain and numbness experienced in four types of peripheral neuropathy patients during 60 day administration of the an amino acid formulation.
Eligible Conditions
- Neuropathy
- Diabetic Neuropathy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 60 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
VAS
Secondary outcome measures
NTSS-6
Routine Blood Panel
Trial Design
1Treatment groups
Experimental Treatment
Group I: Neuron012703Experimental Treatment1 Intervention
Amino acid formulation for the dietary management of symptoms related to periphal neuropathy.
Find a Location
Who is running the clinical trial?
Targeted Medical PharmaLead Sponsor
7 Previous Clinical Trials
434 Total Patients Enrolled
Gabriel Halperin, DPMPrincipal InvestigatorGabriel Halperin DPM Inc.
Share this study with friends
Copy Link
Messenger